Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy

Current Urology Reports

Volumn 16, Issue 11, 2015, Pages

  Feuerstein, Michael A ^a   Goenka, Anuj ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Bladder cancer; Patient reported outcomes; Quality of life; Radiotherapy

Indexed keywords

GEMCITABINE;

BLADDER CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CYSTECTOMY; DRUG DOSE ESCALATION; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION RETRIEVAL; MEDLINE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; SAMPLE SIZE; SEXUAL FUNCTION; TREATMENT FAILURE; MULTIMODALITY CANCER THERAPY; PROCEDURES; TREATMENT OUTCOME; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; NEOPLASM INVASIVENESS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84941216964     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-015-0547-1     Document Type: Review

References (18)

1. Botteman MF, Pashos CL, Hauser RS, et al. Quality of life aspects of bladder cancer: a review of the literature. Qual Life Res. 2003;12:675.
2. Porter MP, Penson DF. Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol. 2005;173:1318.
3. Shabsigh A, Korets R, Vora KC, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55:164.
4. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014. This pooled analysis from five prospective bladder-preserving protocols provides a high level of evidence for efficacy and safety of combined-modailty therapy. At a median follow-up of 4.3 years for all patients, 5- and 10-year overall and disease-free survival rates were comparable to similarly staged patients undergoing radical cystectomy.
5. Basch E, Abernethy AP, Mullins CD, et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30:4249. Recommendations for methodological standards for measuring and reporting patient-reported outcomes in comparative effectiveness trials in oncology.
6. Howie L, Hirsch B, Locklear T, et al. Assessing the value of patient-generated data to comparative effectiveness research. Health Aff (Millwood). 2014;33:1220.
7. Henningsohn L, Wijkstrom H, Dickman PW, et al. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002;62:215.
8. Herman JM, Smith DC, Montie J, et al. Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy. Urology. 2004;64:69.
9. Lagrange JL, Bascoul-Mollevi C, Geoffrois L, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97–015). Int J Radiat Oncol Biol Phys. 2011;79:172. This prospective trial reported quality-of-life outcomes for bladder-preserving multimodal therapy in patients suitable for radical cystectomy. With a median follow-up of 8 years, the authors report satisfactory quality-of-life and quality of bladder function in two-thirds of patients.
10. Zietman AL, Sacco D, Skowronski U, et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol. 2003;170:1772.
11. Caffo O, Fellin G, Graffer U. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. a survey by a self-administered questionnaire. Cancer. 1996;78:1089.
12. Little FA, Howard GC. Sexual function following radical radiotherapy for bladder cancer. Radiother Oncol. 1998;49:157.
13. Rodel C, Weiss C. Organ-sparing multimodality treatment for muscle-invasive bladder cancer: can we continue to ignore the evidence? J Clin Oncol. 2014.
14. Efstathiou JA, Bae K, Shipley WU, et al. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89–03, 95–06, 97–06, 99–06. J Clin Oncol. 2009;27:4055.
15. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649.
16. Roeske JC, Bonta D, Mell LK, et al. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201.
17. Sondergaard J, Hoyer M, Petersen JB, et al. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy. Acta Oncol. 2009;48:238.
18. Calvert M, Blazeby J, Altman DG, et al. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA. 2013;309:814.